USA: A new systematic review published in the Cochrane Database of Systematic Reviews suggests that blue light-enhanced ...

In a trial of low-grade Ta bladder cancer, photocoagulation was noninferior to standard TURBT in maintaining recurrence-free survival. Office-based laser photocoagulation provides 12-month ...

Bladder cancer is a complex disease that poses high risks of morbidity and mortality, especially when not treated optimally. Hematuria is the most common presenting symptom in patients with bladder ...

In a trial, ERAS for ambulatory TURBT showed promise for improving early recovery compared with usual care. In a trial, quality of recovery was significantly better for patients receiving an enhanced ...

UGN-102 had similar disease-free survival outcomes in non-muscle-invasive bladder cancer, regardless of whether the therapy was given with surgery. Groups of patients with newly diagnosed and ...

Nov. 12—(StatePoint) When John noticed blood in his urine, he consulted his doctor and was quickly referred to a urologist. (John is a composite character, based on the experiences of real-life ...

Investigators pooled data from 4 trials to evaluate risk for recurrence in patients with intermediate risk non-muscle-invasive bladder cancer.

Analysis of Tumor Microenvironmental Features Between Primary and Synchronous Liver Metastases From Patients With Colorectal Cancers Using a Deep Learning Algorithm We present an automated tumor risk ...

UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...

PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...